Excipient expert Roquette has successfully completed the acquisition of IFF Pharma Solutions.
This follows the company's prior acquisition of hard capsule manufacturer, Qualicaps, which took place in 2023.
Roquette's acquisition of IFF Pharma Solutions falls in line with the company's long-term strategy, which involves numerous investments into its portfolio of high-value drug delivery solutions.
Through this deal, Roquette will have access to IFF Pharma's range of biopolymers, cellulosics and seaweed extracts, as well as other excipients designed to improve the performance and stability of pharmaceutical oral solid dosage forms (OSDs).
Together, the companies will serve customers across the biotech and pharmaceutical markets, offering solutions to common OSD challenges such as potency, stability and safety.
“The successful acquisition of IFF Pharma Solutions marks a major step forward in our value-creation journey," noted Pierre Courduroux, CEO of Roquette.
"This pivotal move aligns perfectly with our vision to provide unique, high-quality excipients that improve the efficacy and safety of pharmaceutical formulations."
"By combining our strengths, we hope to become the pharmaceutical industry's go-to partner for the development of drug delivery solutions that contribute to improving, sustaining and saving patients' lives," he concluded.